Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sagimet Biosciences Inc. (SGMT)
USD7.68
-0.07 (-0.92%)
US NASDAQ Healthcare Biotechnology
Address
155 Bovet Road 94402
San Mateo, CA, US
San Mateo, CA, US
CEO
David Happel
Website
sagimet.com
IPO
2023-07-14
CIK 1400118 ISIN US7867001049
Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD7.68
-0.07 (-0.92%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
3.44
Float Shares
31.21M
Free Float %
95.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.28% | +1.67% | -9.22% | +27.67% | +0.97% | +23.14% | +108.88% | -54.29% | -54.29% | -54.29% | -54.29% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
7.68
Low
8.00
+4.1%
Consensus
8.00
+4.1%
Median
8.00
+4.1%
High
8.00
+4.1%
DCF (Unlevered)
1.05
-86.4%
DCF (Levered)
1.08
-85.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
90% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
8.00
+4.1%
|
| All Time | 2 |
7.00
-8.9%
|
Quality scores
Altman Z-Score
21.91
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-9.0% Q1'26: +41.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +2,294.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.2% ★ Q1'26: +1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 7 EPS Ana. |
Dec 2027 6 Rev. Ana. 7 EPS Ana. |
Dec 2028 8 Rev. Ana. 8 EPS Ana. |
Dec 2029 7 Rev. Ana. 6 EPS Ana. |
Dec 2030 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
2.00M
est: 2.00M (+0.0%)
|
—
|
—
est: 1.00M (-100.0%)
|
111.1K
111.1K – 111.1K
-88.9% YoY
|
7.53M
7.53M – 7.53M
+6,673.9% YoY
|
23.87M
23.87M – 23.87M
+217.1% YoY
|
91.45M
91.45M – 91.45M
+283.1% YoY
|
252.46M
252.46M – 252.46M
+176.1% YoY
|
| EBITDA |
-30.74M
est: 1.20M (-2,661.7%)
|
-45.57M
|
-56.89M
est: 600.0K (-9,581.5%)
|
66.7K
66.7K – 66.7K
-88.9% YoY
|
4.52M
4.52M – 4.52M
+6,673.9% YoY
|
14.32M
14.32M – 14.32M
+217.1% YoY
|
54.87M
54.87M – 54.87M
+283.1% YoY
|
151.48M
151.48M – 151.48M
+176.1% YoY
|
| EBIT |
-30.74M
est: 1.20M (-2,661.7%)
|
-45.57M
|
-56.89M
est: 600.0K (-9,581.5%)
|
66.7K
66.7K – 66.7K
-88.9% YoY
|
4.52M
4.52M – 4.52M
+6,673.9% YoY
|
14.32M
14.32M – 14.32M
+217.1% YoY
|
54.87M
54.87M – 54.87M
+283.1% YoY
|
151.48M
151.48M – 151.48M
+176.1% YoY
|
| Net Income |
-27.88M
est: -51.09M (+45.4%)
|
-45.57M
est: -50.67M (+10.1%)
|
-51.04M
est: -53.67M (+4.9%)
|
-39.99M
-49.94M – -30.03M
+25.5% YoY
|
-39.25M
-53.67M – -24.83M
+1.8% YoY
|
-63.61M
-98.15M – -29.07M
-62.1% YoY
|
-31.81M
-31.81M – -31.81M
+50.0% YoY
|
11.86M
11.86M – 11.86M
+137.3% YoY
|
| SGA |
12.96M
est: 4.19M (+209.2%)
|
16.01M
|
17.84M
est: 2.10M (+750.8%)
|
232.9K
232.9K – 232.9K
-88.9% YoY
|
15.78M
15.78M – 15.78M
+6,673.9% YoY
|
50.04M
50.04M – 50.04M
+217.1% YoY
|
191.70M
191.70M – 191.70M
+283.1% YoY
|
529.23M
529.23M – 529.23M
+176.1% YoY
|
| EPS |
-1.53
est: -1.58 (+3.1%)
|
-1.45
est: -1.57 (+7.5%)
|
-1.58
est: -1.66 (+5.1%)
|
-1.20
-1.54 – -0.93
+27.9% YoY
|
-1.25
-1.66 – -0.77
-4.2% YoY
|
-1.63
-3.03 – -0.90
-30.1% YoY
|
-0.98
-0.98 – -0.98
+39.5% YoY
|
0.37
0.37 – 0.37
+137.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-19 | Citizens | Market Outperform | Market Outperform | Maintain |
| 2026-05-04 | Canaccord Genuity | Buy | Buy | Maintain |
| 2026-04-29 | Guggenheim | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-39.72M
OE per share TTM
-1.23
Owner's Yield
-16.74%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
64.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
92
Total invested
69.76M
Insider transactions (90d)
1
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Blue Owl Capital Holdings LP | 1.67M | 5.46% | 1.67M | — | 1.67M | — | PN | Delaware | 2024-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
92
-2 vs prev Q
New positions
17
Closed positions
17
Increased
50
Reduced
17
Put/Call ratio
0.65
Calls held
252.0K
Puts held
163.1K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | DUMAC, INC. | 71.2K +71.2K (+100.0%) | 421.46M +421.5M (+100.0%) | 0.22% +0.219 pp | 0.06% +0.065 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 1.26M +56.3K (+4.7%) | 7.46M -797.6K (-9.7%) | 3.88% +0.142 pp | 0.00% +0.000 pp | USD5.88 +0.7% | 10 qtrs — |
| 3 | BLUE OWL CAPITAL HOLDINGS LP | 1.24M -84.5K (-6.4%) | 7.36M -1.7M (-19.2%) | 3.83% -0.295 pp | 0.55% -2.278 pp | USD5.26 +12.5% | 9 qtrs — |
| 4 | AFFINITY ASSET ADVISORS, LLC | 1.15M +798.2K (+228.1%) | 6.80M +4.4M (+183.1%) | 3.54% +2.450 pp | 0.39% +0.178 pp | USD6.21 -4.7% | 2 qtrs — |
| 5 | WOODLINE PARTNERS LP | 1.00M -500.4K (-33.3%) | 5.93M -4.4M (-42.5%) | 3.08% -1.580 pp | 0.02% -0.026 pp | USD7.62 -22.3% | 3 qtrs — |
| 6 | BAKER BROS. ADVISORS LP | 953.0K +— (+0.0%) | 5.64M -895.8K (-13.7%) | 2.94% -0.025 pp | 0.03% -0.014 pp | USD7.31 -19.0% | 10 qtrs — |
| 7 | BLACKROCK, INC. | 814.0K +201.2K (+32.8%) | 4.82M +615.4K (+14.6%) | 2.51% +0.604 pp | 0.00% +0.000 pp | USD4.23 +40.0% | 6 qtrs — |
| 8 | MARSHALL WACE, LLP | 780.4K +780.4K (+100.0%) | 4.62M +4.6M (+100.0%) | 2.40% +2.404 pp | 0.00% +0.004 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 9 | HHLR ADVISORS, LTD. | 724.8K +— (+0.0%) | 4.29M -681.3K (-13.7%) | 2.23% -0.019 pp | 0.14% +0.017 pp | USD8.80 -32.7% | 10 qtrs — |
| 10 | SIREN, L.L.C. | 724.8K +— (+0.0%) | 4.29M -681.3K (-13.7%) | 2.23% -0.019 pp | 0.13% -0.067 pp | USD2.77 +113.7% | 6 qtrs — |
| 11 | MILLENNIUM MANAGEMENT LLC | 586.9K -189.4K (-24.4%) | 3.47M -1.9M (-34.8%) | 1.81% -0.604 pp | 0.00% -0.001 pp | USD6.65 -11.0% | 10 qtrs — |
| 12 | D. E. SHAW & CO., INC. | 485.5K -215.7K (-30.8%) | 2.87M -1.9M (-40.3%) | 1.50% -0.683 pp | 0.00% -0.001 pp | USD7.02 -15.7% | 3 qtrs — |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 342.5K +181.1K (+112.2%) | 2.03M +920.4K (+83.1%) | 1.06% +0.554 pp | 0.00% +0.002 pp | USD6.43 -7.9% | 9 qtrs — |
| 14 | HUDSON BAY CAPITAL MANAGEMENT LP | 304.5K +304.5K (+100.0%) | 1.80M +1.8M (+100.0%) | 0.94% +0.938 pp | 0.01% +0.006 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 15 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 299.6K +— (+0.0%) | 1.77M -281.7K (-13.7%) | 0.92% -0.008 pp | 0.04% -0.007 pp | USD6.52 -9.2% | 9 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 295.9K +12.6K (+4.5%) | 1.75M -191.5K (-9.9%) | 0.91% +0.032 pp | 0.00% +0.000 pp | USD5.09 +16.3% | 10 qtrs — |
| 17 | RAYMOND JAMES FINANCIAL INC | 286.3K +8.0K (+2.9%) | 1.69M -214.2K (-11.2%) | 0.88% +0.018 pp | 0.00% 0.000 pp | USD3.51 +68.7% | 4 qtrs — |
| 18 | PALE FIRE CAPITAL SE | 221.9K +221.9K (+100.0%) | 1.31M +1.3M (+100.0%) | 0.68% +0.683 pp | 0.09% +0.088 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 19 | UBS GROUP AG | 201.8K -105.0K (-34.2%) | 1.19M -910.0K (-43.2%) | 0.62% -0.331 pp | 0.00% 0.000 pp | USD4.59 +29.0% | 10 qtrs — |
| 20 | POINT72 ASSET MANAGEMENT, L.P. | 175.8K +175.8K (+100.0%) | 1.04M +1.0M (+100.0%) | 0.54% +0.542 pp | 0.00% +0.001 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 21 | VERITION FUND MANAGEMENT LLC | 154.7K +154.7K (+100.0%) | 915.6K +915.6K (+100.0%) | 0.48% +0.476 pp | 0.00% +0.004 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 22 | FNY INVESTMENT ADVISERS, LLC | 142.9K +32.2K (+29.1%) | 845.0K +86.0K (+11.3%) | 0.44% +0.096 pp | 0.24% -0.006 pp | USD4.61 +28.4% | 8 qtrs — |
| 23 | DIMENSIONAL FUND ADVISORS LP | 136.0K +110.7K (+437.0%) | 805.3K +631.5K (+363.3%) | 0.42% +0.340 pp | 0.00% +0.000 pp | USD5.66 +4.6% | 5 qtrs — |
| 24 | 683 CAPITAL MANAGEMENT, LLC | 126.3K +126.3K (+100.0%) | 748.0K +748.0K (+100.0%) | 0.39% +0.389 pp | 0.03% +0.033 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 25 | GOLDMAN SACHS GROUP INC | 125.9K +110.8K (+729.0%) | 745.6K +641.4K (+615.4%) | 0.39% +0.341 pp | 0.00% +0.000 pp | USD5.62 +5.3% | 10 qtrs — |
| 26 | STATE STREET CORP | 117.4K +6.9K (+6.2%) | 694.9K -63.0K (-8.3%) | 0.36% +0.018 pp | 0.00% +0.000 pp | USD5.16 +14.7% | 10 qtrs — |
| 27 | QUBE RESEARCH & TECHNOLOGIES LTD | 111.3K +4.5K (+4.2%) | 659.2K -73.8K (-10.1%) | 0.34% +0.011 pp | 0.00% 0.000 pp | USD6.82 -13.2% | 5 qtrs — |
| 28 | RB CAPITAL MANAGEMENT, LLC | 97.0K +97.0K (+100.0%) | 574.2K +574.2K (+100.0%) | 0.30% +0.299 pp | 0.11% +0.114 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 29 | CITADEL ADVISORS LLC | 92.6K +47.4K (+104.9%) | 548.2K +238.1K (+76.8%) | 0.29% +0.145 pp | 0.00% +0.000 pp | USD6.02 -1.7% | 7 qtrs — |
| 30 | JANE STREET GROUP, LLC | 92.4K +79.6K (+619.9%) | 547.2K +459.1K (+521.2%) | 0.28% +0.245 pp | 0.00% +0.000 pp | USD5.72 +3.5% | 8 qtrs — |
| 31 | XTX TOPCO LTD | 91.7K +32.0K (+53.6%) | 543.1K +133.3K (+32.5%) | 0.28% +0.097 pp | 0.01% -0.007 pp | USD6.23 -5.0% | 4 qtrs — |
| 32 | MORGAN STANLEY | 89.2K -156.8K (-63.7%) | 528.3K -1.2M (-68.7%) | 0.27% -0.489 pp | 0.00% 0.000 pp | USD4.43 +33.6% | 10 qtrs — |
| 33 | SQUAREPOINT OPS LLC | 84.7K +49.7K (+141.6%) | 501.6K +261.1K (+108.5%) | 0.26% +0.152 pp | 0.00% +0.000 pp | USD6.31 -6.2% | 2 qtrs — |
| 34 | BNP PARIBAS ARBITRAGE, SNC | 75.1K +74.8K (+20,943.7%) | 444.7K +442.3K (+18,060.3%) | 0.23% +0.230 pp | 0.00% +0.000 pp | USD5.93 -0.2% | 5 qtrs — |
| 35 | KESTRA ADVISORY SERVICES, LLC | 66.0K +66.0K (+100.0%) | 390.8K +390.8K (+100.0%) | 0.20% +0.203 pp | 0.00% +0.002 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 36 | AMERICAN CENTURY COMPANIES INC | 61.4K +2.9K (+5.0%) | 363.4K -37.6K (-9.4%) | 0.19% +0.008 pp | 0.00% +0.000 pp | USD4.99 +18.6% | 5 qtrs — |
| 37 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 56.5K -105.4K (-65.1%) | 334.5K -776.2K (-69.9%) | 0.17% -0.329 pp | 0.00% 0.000 pp | USD6.24 -5.1% | 5 qtrs — |
| 38 | NORTHERN TRUST CORP | 55.5K +3.2K (+6.1%) | 328.6K -30.1K (-8.4%) | 0.17% +0.009 pp | 0.00% +0.000 pp | USD5.52 +7.2% | 10 qtrs — |
| 39 | OMERS ADMINISTRATION CORP | 53.4K +53.4K (+100.0%) | 316.1K +316.1K (+100.0%) | 0.16% +0.165 pp | 0.00% +0.002 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 40 | TWO SIGMA INVESTMENTS, LP | 42.5K -8.7K (-16.9%) | 251.8K -99.4K (-28.3%) | 0.13% -0.028 pp | 0.00% 0.000 pp | USD6.08 -2.6% | 9 qtrs — |
| 41 | HIGHTOWER ADVISORS, LLC | 37.2K +3.4K (+10.1%) | 220.2K -11.6K (-5.0%) | 0.11% +0.010 pp | 0.00% +0.000 pp | USD7.42 -20.2% | 3 qtrs — |
| 42 | MAN GROUP PLC | 35.6K -11.3K (-24.2%) | 210.8K -111.3K (-34.5%) | 0.11% -0.036 pp | 0.00% 0.000 pp | USD6.86 -13.7% | 2 qtrs — |
| 43 | MARINER, LLC | 32.1K +7.0K (+27.9%) | 190.0K +17.8K (+10.4%) | 0.10% +0.021 pp | 0.00% +0.000 pp | USD4.98 +18.9% | 4 qtrs — |
| 44 | ABACUS PLANNING GROUP, INC. | 30.0K +— (+0.0%) | 177.4K -28.2K (-13.7%) | 0.09% -0.001 pp | 0.02% -0.005 pp | USD3.82 +55.0% | 4 qtrs — |
| 45 | BARCLAYS PLC | 29.3K -27.9K (-48.7%) | 173.7K +15.2K (+9.6%) | 0.09% -0.087 pp | 0.00% +0.000 pp | USD6.86 -13.7% | 9 qtrs — |
| 46 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 25.9K +3.2K (+14.1%) | 153.3K -2.4K (-1.5%) | 0.08% +0.009 pp | 0.01% +0.000 pp | USD6.74 -12.2% | 2 qtrs — |
| 47 | GSA CAPITAL PARTNERS LLP | 25.2K -60.1K (-70.4%) | 149.0K -436.0K (-74.5%) | 0.08% -0.187 pp | 0.01% -0.036 pp | USD6.86 -13.7% | 5 qtrs — |
| 48 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 22.7K +22.7K (+100.0%) | 134.6K +134.6K (+100.0%) | 0.07% +0.070 pp | 0.00% +0.004 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 49 | DEKABANK DEUTSCHE GIROZENTRALE | 20.0K +— (+0.0%) | 125.0K -11.0K (-8.1%) | 0.06% -0.001 pp | 0.00% +0.000 pp | USD5.23 +13.2% | 8 qtrs — |
| 50 | LPL FINANCIAL LLC | 20.6K +4.9K (+31.3%) | 121.8K +14.3K (+13.3%) | 0.06% +0.015 pp | 0.00% +0.000 pp | USD6.64 -10.8% | 2 qtrs — |
| 51 | CRESSET ASSET MANAGEMENT, LLC | 20.1K +20.1K (+100.0%) | 118.9K +118.9K (+100.0%) | 0.06% +0.062 pp | 0.00% +0.001 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 52 | CITIGROUP INC | 18.0K +18.0K (+100.0%) | 106.4K +106.4K (+100.0%) | 0.06% +0.055 pp | 0.00% +0.000 pp | USD5.92 +0.0% | 9 qtrs — |
| 53 | 1492 CAPITAL MANAGEMENT LLC | 15.0K +— (+0.0%) | 88.8K -14.1K (-13.7%) | 0.05% 0.000 pp | 0.03% -0.008 pp | USD6.86 -13.7% | 2 qtrs — |
| 54 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 15.0K +— (+0.0%) | 88.8K -14.1K (-13.7%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD3.26 +81.6% | 4 qtrs — |
| 55 | SIMPLEX TRADING, LLC | 14.2K +14.2K (+100.0%) | 84.2K +84.2K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.000 pp | USD5.92 +0.0% | 7 qtrs — |
| 56 | JEFFERIES FINANCIAL GROUP INC. | 13.2K -695.0 (-5.0%) | 78.2K -17.2K (-18.0%) | 0.04% -0.003 pp | 0.00% 0.000 pp | USD6.86 -13.7% | 2 qtrs — |
| 57 | JASPER RIDGE PARTNERS, L.P. | 12.9K -6.1K (-32.3%) | 76.2K -54.2K (-41.6%) | 0.04% -0.019 pp | 0.00% -0.001 pp | USD3.26 +81.6% | 4 qtrs — |
| 58 | HAMILTON LANE ADVISORS LLC | 11.1K +11.1K (+100.0%) | 65.7K +65.7K (+100.0%) | 0.03% +0.034 pp | 0.04% +0.036 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 59 | VIRTU FINANCIAL LLC | 10.4K +10.4K (+100.0%) | 62.0K +62.0K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.002 pp | USD5.92 +0.0% | 9 qtrs — |
| 60 | SHERBROOKE PARK ADVISERS LLC | 10.1K +10.1K (+100.0%) | 60.0K +60.0K (+100.0%) | 0.03% +0.031 pp | 0.15% +0.155 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 61 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 10.1K +10.1K (+100.0%) | 59.7K +59.7K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.001 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 62 | WEDMONT PRIVATE CAPITAL | 10.8K +10.8K (+100.0%) | 59.6K +59.6K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.002 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 63 | BANK OF AMERICA CORP /DE/ | 9.9K -15.8K (-61.6%) | 58.5K -117.9K (-66.8%) | 0.03% -0.049 pp | 0.00% +0.000 pp | USD6.43 -7.9% | 10 qtrs — |
| 64 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 9.0K +— (+0.0%) | 53.3K -8.5K (-13.7%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD6.86 -13.7% | 2 qtrs — |
| 65 | WELLS FARGO & COMPANY/MN | 8.0K +1.0K (+14.3%) | 47.4K -660.0 (-1.4%) | 0.02% +0.003 pp | 0.00% +0.000 pp | USD4.21 +40.6% | 5 qtrs — |
| 66 | ACADIAN ASSET MANAGEMENT LLC | 8.0K +8.0K (+100.0%) | 46.0K +46.0K (+100.0%) | 0.02% +0.025 pp | 0.00% +0.000 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 67 | QUEST PARTNERS LLC | 6.2K -111.1K (-94.7%) | 36.6K -767.8K (-95.5%) | 0.02% -0.345 pp | 0.00% -0.051 pp | USD6.86 -13.7% | 2 qtrs — |
| 68 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 5.1K +5.1K (+100.0%) | 29.9K +29.9K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.002 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 69 | ROYAL BANK OF CANADA | 4.9K +4.4K (+819.2%) | 29.0K +26.0K (+866.7%) | 0.02% +0.014 pp | 0.00% +0.000 pp | USD5.84 +1.4% | 4 qtrs — |
| 70 | ANTIPODES PARTNERS LTD | 3.2K +— (+0.0%) | 18.8K -3.0K (-13.7%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD7.62 -22.3% | 3 qtrs — |
| 71 | GLOBAL RETIREMENT PARTNERS, LLC | 3.0K +— (+0.0%) | 17.8K -2.8K (-13.7%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD7.62 -22.3% | 3 qtrs — |
| 72 | JPMORGAN CHASE & CO | 2.5K +2.4K (+2,438.8%) | 14.7K +14.1K (+2,091.8%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD5.85 +1.2% | 10 qtrs — |
| 73 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 1.5K +1.5K (+100.0%) | 8.9K +8.9K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 74 | VSM WEALTH ADVISORY, LLC | 1.5K +1.5K (+100.0%) | 8.9K +8.9K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.003 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 75 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 1.5K +— (+0.0%) | 8.9K -1.4K (-13.7%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD4.50 +31.6% | 9 qtrs — |
| 76 | PARALLEL ADVISORS, LLC | 849.00 +849.0 (+100.0%) | 5.0K +5.0K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 77 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 823.00 +823.0 (+100.0%) | 4.9K +4.9K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.001 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 78 | TOTH FINANCIAL ADVISORY CORP | 650.00 +— (+0.0%) | 3.8K -611.0 (-13.7%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD7.62 -22.3% | 3 qtrs — |
| 79 | GF FUND MANAGEMENT CO. LTD. | 608.00 +608.0 (+100.0%) | 3.6K +3.6K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 80 | MAI CAPITAL MANAGEMENT | 500.00 +— (+0.0%) | 3.0K -470.0 (-13.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.81 +110.7% | 6 qtrs — |
| 81 | SMARTLEAF ASSET MANAGEMENT LLC | 500.00 +500.0 (+100.0%) | 2.9K +2.9K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 82 | RIALTO WEALTH MANAGEMENT, LLC | 359.00 +— (+0.0%) | 2.1K -337.0 (-13.7%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD7.62 -22.3% | 3 qtrs — |
| 83 | PHYSICIAN WEALTH ADVISORS, INC. | 317.00 +— (+0.0%) | 1.9K -298.0 (-13.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.62 -22.3% | 3 qtrs — |
| 84 | FEDERATED HERMES, INC. | 262.00 -301.0 (-53.5%) | 1.6K -2.3K (-59.8%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD6.86 -13.7% | 2 qtrs — |
| 85 | FMR LLC | 133.00 -46.0 (-25.7%) | 788.00 -442.0 (-35.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD7.41 -20.1% | 10 qtrs — |
| 86 | SRS CAPITAL ADVISORS, INC. | 115.00 +— (+0.0%) | 681.00 -108.0 (-13.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.85 -13.6% | 2 qtrs — |
| 87 | SBI SECURITIES CO., LTD. | 24.00 -12.0 (-33.3%) | 142.00 -105.0 (-42.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.92 +0.0% | 5 qtrs — |
| 88 | ORG WEALTH PARTNERS, LLC | — -17.8K (-100.0%) | — -122.0K (-100.0%) | 0.00% -0.055 pp | 0.00% -0.026 pp | USD— | 6 qtrs SOLD |
| 89 | READYSTATE ASSET MANAGEMENT LP | — -325.4K (-100.0%) | — -2.2M (-100.0%) | 0.00% -1.011 pp | 0.00% -0.095 pp | USD— | 3 qtrs SOLD |
| 90 | US BANCORP \DE\ | — -1.0K (-100.0%) | — -6.9K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 91 | RISE ADVISORS, LLC | — -306.0 (-100.0%) | — -2.1K (-100.0%) | 0.00% -0.001 pp | 0.00% -0.001 pp | USD— | 3 qtrs SOLD |
| 92 | GRAHAM CAPITAL MANAGEMENT, L.P. | — -49.1K (-100.0%) | — -336.5K (-100.0%) | 0.00% -0.152 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
| 93 | SCHONFELD STRATEGIC ADVISORS LLC | — -523.8K (-100.0%) | — -3.6M (-100.0%) | 0.00% -1.627 pp | 0.00% -0.020 pp | USD— | 8 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 54 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Health Innovation Active ETF BMED | 0.11% | 12.4K | 0.77% |
| 2 | iShares Micro-Cap ETF IWC | 0.10% | 1.46M | 0.60% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.07% | 7.27M | 0.35% |
| 4 | Global X - S&P Biotech ETF CURE.AX | 0.07% | 23.4K | 0.45% |
| 5 | iShares Biotechnology ETF IBB | 0.03% | 3.10M | 0.44% |
| 6 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 143.3K | 0.40% |
| 7 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.03% | 23.2K | 0.19% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 22.7K | 0.35% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.03% | 339.6K | 0.35% |
| 10 | iShares Russell 2000 Growth ETF IWO | 0.02% | 3.19M | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.00
Bullish
Ratio by volume
3.00
Bullish
Buys
8
Sells
4
Shares acquired
780.0K
Shares disposed
19.7K
Cash buys
—
Cash sales
4.00
Net activity
+760,325
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Grauer Andreas | Officer | A-Award | A | Stock Option (Right to Buy) | 264,759 | 6.44 | 1.71M | 264,759 | D | ↗ |
| 2026-02-19 | Rozek Elizabeth | Officer | A-Award | A | Series A Common Stock | 44,000 | 0.00 | — | 234,959 | D | ↗ |
| 2026-02-19 | Martins Eduardo Bruno | Officer | A-Award | A | Series A Common Stock | 44,000 | 0.00 | — | 147,296 | D | ↗ |
| 2026-02-19 | Happel David | Director / Officer | A-Award | A | Series A Common Stock | 128,000 | 0.00 | — | 805,621 | D | ↗ |
| 2026-02-19 | Chauche Thierry | Officer | A-Award | A | Stock Option (Right to Buy) | 88,000 | 5.38 | 473.4K | 88,000 | D | ↗ |
| 2026-02-10 | Rozek Elizabeth | Officer | S-Sale | D | Series A Common Stock | 2,622 | 5.36 | 14.1K | 190,959 | D | ↗ |
| 2026-02-10 | Martins Eduardo Bruno | Officer | S-Sale | D | Series A Common Stock | 3,640 | 5.36 | 19.5K | 103,296 | D | ↗ |
| 2026-02-10 | Happel David | Director / Officer | S-Sale | D | Series A Common Stock | 12,101 | 5.36 | 64.9K | 677,621 | D | ↗ |
| 2026-02-10 | Chauche Thierry | Officer | S-Sale | D | Series A Common Stock | 1,312 | 5.36 | 7.0K | 15,688 | D | ↗ |
| 2025-11-20 | Kemble George | Director / Officer | S-Sale | D | Series A Common Stock | 37,688 | 7.69 | 290.0K | 81,005 | D | ↗ |
| 2025-11-04 | Rozek Elizabeth | Officer | A-Award | A | Series A Common Stock | 9,855 | 0.00 | — | 193,581 | D | ↗ |
| 2025-07-21 | Rozek Elizabeth | Officer | S-Sale | D | Series A Common Stock | 10,780 | 9.13 | 98.5K | 183,726 | D | ↗ |
| 2025-07-21 | Martins Eduardo Bruno | Officer | S-Sale | D | Series A Common Stock | 8,277 | 9.13 | 75.6K | 106,936 | D | ↗ |
| 2025-07-21 | Happel David | Director / Officer | S-Sale | D | Series A Common Stock | 65,478 | 9.13 | 598.1K | 689,722 | D | ↗ |
| 2025-06-09 | Walbert Timothy P | Director | A-Award | A | Stock Option (Right to Buy) | 32,250 | 5.33 | 171.9K | 32,250 | D | ↗ |
| 2025-06-09 | SEIDENBERG BETH C | Director | A-Award | A | Stock Option (Right to Buy) | 32,250 | 5.33 | 171.9K | 32,250 | D | ↗ |
| 2025-06-09 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 27,268 | 5.33 | 145.3K | 27,268 | D | ↗ |
| 2025-06-09 | Kemble George | Director | A-Award | A | Stock Option (Right to Buy) | 32,250 | 5.33 | 171.9K | 32,250 | D | ↗ |
| 2025-06-09 | Jarrett Jennifer | Director | A-Award | A | Stock Option (Right to Buy) | 27,268 | 5.33 | 145.3K | 27,268 | D | ↗ |
| 2025-06-09 | Hoelscher Paul W. | Director | A-Award | A | Stock Option (Right to Buy) | 32,250 | 5.33 | 171.9K | 32,250 | D | ↗ |
| 2025-06-09 | GRAMMER ELIZABETH A | Director | A-Award | A | Stock Option (Right to Buy) | 32,250 | 5.33 | 171.9K | 32,250 | D | ↗ |
| 2025-06-06 | SEIDENBERG BETH C | Director | A-Award | A | Stock Option (Right to Buy) | 28,522 | 5.56 | 158.6K | 28,522 | D | ↗ |
| 2025-02-06 | Rozek Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 138,000 | 4.71 | 650.0K | 138,000 | D | ↗ |
| 2025-02-06 | Martins Eduardo Bruno | Officer | A-Award | A | Series A Common Stock | 34,000 | 0.00 | — | 115,213 | D | ↗ |
| 2025-02-06 | Happel David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 472,000 | 4.71 | 2.22M | 472,000 | D | ↗ |
| 2025-02-06 | Chauche Thierry | Officer | A-Award | A | Series A Common Stock | 17,000 | 0.00 | — | 17,000 | D | ↗ |
| 2024-08-01 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 113,895 | 3.48 | 396.4K | 113,895 | — | ↗ |
| 2024-08-01 | Jarrett Jennifer | Director | A-Award | A | Stock Option (Right to Buy) | 113,895 | 3.48 | 396.4K | 113,895 | — | ↗ |
| 2024-07-23 | Kemble George | Director / Officer | S-Sale | D | Series A Common Stock | 23,625 | 3.17 | 74.8K | 118,693 | — | ↗ |
| 2024-07-19 | Rozek Elizabeth | Officer | S-Sale | D | Series A Common Stock | 10,914 | 3.10 | 33.8K | 160,506 | — | ↗ |
| 2024-07-19 | Martins Eduardo Bruno | Officer | S-Sale | D | Series A Common Stock | 8,357 | 3.10 | 25.9K | 81,213 | — | ↗ |
| 2024-07-19 | Kemble George | Director / Officer | S-Sale | D | Series A Common Stock | 14,062 | 3.10 | 43.6K | 142,318 | — | ↗ |
| 2024-06-05 | Walbert Timothy P | Director | A-Award | A | Stock Option (Right to Buy) | 9,279 | 4.64 | 43.1K | 9,279 | — | ↗ |
| 2024-06-05 | SEIDENBERG BETH C | Director | A-Award | A | Stock Option (Right to Buy) | 51,459 | 4.64 | 238.8K | 51,459 | — | ↗ |
| 2024-06-05 | Parsey Merdad | Director | A-Award | A | Stock Option (Right to Buy) | 51,459 | 4.64 | 238.8K | 51,459 | — | ↗ |
| 2024-06-05 | Hoelscher Paul W. | Director | A-Award | A | Stock Option (Right to Buy) | 9,279 | 4.64 | 43.1K | 9,279 | — | ↗ |
| 2024-06-05 | GRAMMER ELIZABETH A | Director | A-Award | A | Stock Option (Right to Buy) | 51,459 | 4.64 | 238.8K | 51,459 | — | ↗ |
| 2024-05-06 | Chauche Thierry | Officer | A-Award | A | Stock Option (Right to Buy) | 587,181 | 4.28 | 2.51M | 587,181 | — | ↗ |
| 2024-04-01 | Walbert Timothy P | Director | A-Award | A | Stock Option (Right to Buy) | 73,014 | 5.23 | 381.9K | 73,014 | — | ↗ |
| 2024-04-01 | Hoelscher Paul W. | Director | A-Award | A | Stock Option (Right to Buy) | 73,014 | 5.23 | 381.9K | 73,014 | — | ↗ |
| 2024-03-26 | Happel David | Director / Officer | P-Purchase | A | Series A Common Stock | 12,100 | 5.27 | 63.7K | 639,200 | — | ↗ |
| 2024-01-29 | SANDELL SCOTT D | 10% Owner | J-Other | A | Series A Common Stock | 6,997 | 0.00 | — | 6,997 | — | ↗ |
| 2024-01-29 | NEW ENTERPRISE ASSOCIATES 13 LP | 10% Owner | J-Other | D | Series A Common Stock | 850,000 | 0.00 | — | 3,000,275 | — | ↗ |
| 2023-07-18 | NEW ENTERPRISE ASSOCIATES 13 LP | 10% Owner | C-Conversion | D | Series C Preferred Stock | 11,363,634 | 0.00 | — | 0 | — | ↗ |
| 2023-07-18 | GRAMMER ELIZABETH A | Director | D-Return | D | Stock Option (Right to Buy) | 49,533 | 8.74 | 432.9K | 0 | — | ↗ |
| 2023-07-13 | NEW ENTERPRISE ASSOCIATES 13 LP | 10% Owner | — | D | Series B Preferred Stock | 16,370 | 0.00 | — | 0 | — | ↗ |
| 2023-07-13 | GRAMMER ELIZABETH A | Director | — | D | Stock Option (Right to Buy) | 49,533 | 8.74 | 432.9K | 0 | — | ↗ |
| 2014-01-23 | NEW ENTERPRISE ASSOCIATES 13 LP | 10% Owner | — | D | Common Stock Warrant (right to buy) | 13,404 | 0.79 | 10.7K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
32.58M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | David Happel President and Chief Executive Officer | 630.0K | — | 546.4K | 1.75M | 294.5K | 19.4K | 3.24M | 70.87% | ↗ |
| 2 | 2025 | Elizabeth Rozek, Esq. Chief Legal and Administrative Officer | 483.3K | — | 235.1K | 591.7K | 170.0K | 16.6K | 1.50M | 55.24% | ↗ |
| 3 | 2025 | Eduardo Bruno Martins, M.D., D.Phil., Former Chief Medical Officer | 500.0K | — | 160.1K | 511.6K | 170.0K | 19.1K | 1.36M | 49.36% | ↗ |
| 4 | 2024 | Thierry Chauche Chief Financial Officer | 314.5K | — | — | 1.97M | 125.7K | 506.00 | 2.41M | 81.69% | ↗ |
| 5 | 2024 | David Happel President and Chief Executive Officer | 582.0K | — | — | — | 320.1K | 4.1K | 906.2K | 0.00% | ↗ |
| 6 | 2024 | Eduardo Bruno Martins, M.D., D.Phil., Former Chief Medical Officer | 475.0K | — | — | — | 190.0K | 4.1K | 669.1K | 0.00% | ↗ |
| 7 | 2024 | Eduardo Bruno Martins, M.D., D.Phil., Chief Medical Officer | 475.0K | — | — | — | 190.0K | 4.1K | 669.1K | 0.00% | ↗ |
| 8 | 2024 | Elizabeth Rozek, Esq. Chief Legal and Administrative Officer | 446.0K | — | — | — | 178.4K | 1.7K | 626.1K | 0.00% | ↗ |
| 9 | 2023 | David Happel President and Chief Executive Officer | 502.9K | — | 1.85M | — | 329.7K | 3.6K | 2.69M | 68.87% | ↗ |
| 10 | 2023 | Eduardo Bruno Martins, M.D., D.Phil., Chief Medical Officer | 442.9K | — | 265.1K | 594.6K | 202.8K | 3.6K | 1.51M | 56.97% | ↗ |
| 11 | 2023 | George Kemble, Ph.D. Executive Chairman and former President, Chief Executive Officer and Chief Scientific Officer | 458.6K | — | 446.2K | — | — | 25.4K | 930.2K | 47.97% | ↗ |
| 12 | 2023 | Dennis Hom Former Chief Financial Officer | 226.1K | — | — | — | — | 519.4K | 745.5K | 0.00% | ↗ |
| 13 | 2022 | David Happel President and Chief Executive Officer | 97.9K | — | — | 6.20M | 211.5K | 297.00 | 6.51M | 95.24% | ↗ |
| 14 | 2022 | George Kemble, Ph.D. Executive Chairman and former President, Chief Executive Officer and Chief Scientific Officer | 404.9K | — | — | 129.7K | — | 40.3K | 574.9K | 22.56% | ↗ |
| 15 | 2022 | Eduardo Bruno Martins, M.D., D.Phil., Chief Medical Officer | 411.1K | — | — | — | 125.8K | 297.00 | 537.1K | 0.00% | ↗ |
| 16 | 2022 | Dennis Hom Former Chief Financial Officer | 357.5K | — | — | — | 109.4K | 68.00 | 466.9K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David A. Happel | Chief Executive Officer, President & Director | 943.9K | male |
| Elizabeth Rozek | Chief Legal & Administrative Officer | 669.9K | female |
| Eduardo Bruno Martins DPhil | Chief Medical Officer | 669.1K | — |
| Andreas Grauer | Chief Medical Officer | 669.1K | — |
| Thierry Chauche | Chief Financial Officer & Principal Accounting Officer | 598.0K | male |
| Urs Greber | Co-Founder | — | male |
| Lucas Pelkmans | Co-Founder | — | — |
| Marie O'Farrell | Chief Scientific Officer | — | — |
| Robert D'Urso | Senior Vice President of New Products | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SGMT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
